AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
14 Feb 2019 07:00 AM
RNS
AstraZeneca Full-Year and Q4 2018 Results
06 Feb 2019 07:00 AM
RNS
US FDA grants Fasenra Orphan Drug Designation
05 Feb 2019 07:05 AM
RNS
US FDA grants Breakthrough Therapy Designation
05 Feb 2019 07:00 AM
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 03:00 PM
RNS
Total Voting Rights
01 Feb 2019 01:17 PM
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 02:00 PM
RNS
Completion of divestment of US Synagis rights
07 Jan 2019 01:00 PM
RNS
AstraZeneca announces organisational changes
02 Jan 2019 03:00 PM
RNS
Total Voting Rights
20 Dec 2018 01:47 PM
RNS
Bevespi Aerosphere approved in the EU for COPD
20 Dec 2018 07:05 AM
RNS
Lynparza meets primary endpoint in SOLO-3 trial
20 Dec 2018 07:00 AM
RNS
Phase III ROCKIES and OLYMPUS roxadustat trials
19 Dec 2018 06:31 PM
RNS
FDA approves Lynparza as 1L maintenance therapy
18 Dec 2018 09:09 AM
RNS
Roxadustat approved in China for the treatment of
14 Dec 2018 07:00 AM
RNS
Directorate Change
07 Dec 2018 07:00 AM
RNS
Update on the Phase III EAGLE trial of Imfinzi
06 Dec 2018 07:00 AM
RNS
Divestment of rights to Covis completed
04 Dec 2018 03:00 PM
RNS
Director/PDMR Shareholding
03 Dec 2018 04:00 PM
RNS
Total Voting Rights
03 Dec 2018 04:00 PM
RNS
Block listing Interim Review
03 Dec 2018 07:00 AM
RNS
Grünenthal Agreement for Nexium, Vimovo Completed
26 Nov 2018 07:00 AM
RNS
US FDA grants Fasenra ODD for EGPA
16 Nov 2018 07:00 AM
RNS
AstraZeneca provides update on Phase III MYSTIC
13 Nov 2018 07:00 AM
RNS
AstraZeneca to divest US Synagis rights to Sobi
12 Nov 2018 07:05 AM
RNS
US FDA accepts regulatory submission for Lynparza
12 Nov 2018 07:00 AM
RNS
Farxiga significantly reduced hospitalisation for
08 Nov 2018 07:00 AM
RNS
AZN: Year-to-Date and Q3 2018 Results
06 Nov 2018 07:00 AM
RNS
Divestment of rights to Covis Pharma
01 Nov 2018 03:00 PM
RNS
Total Voting Rights
31 Oct 2018 09:45 AM
RNS
Additional financial information-Grünenthal deal
30 Oct 2018 07:00 AM
RNS
Grünenthal Agreement for rights to Nexium, Vimovo
23 Oct 2018 07:00 AM
RNS
AstraZeneca Extends Innate Pharma Collaboration
22 Oct 2018 07:00 AM
RNS
Lynparza shows 70% reduction in PFS ovarian cancer
19 Oct 2018 01:09 PM
RNS
CHMP positive opinion Bevespi Aerosphere
16 Oct 2018 07:00 AM
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
01 Oct 2018 03:00 PM
RNS
Total Voting Rights
01 Oct 2018 07:00 AM
RNS
Atacand Agreement with Cheplapharm Completed
28 Sep 2018 04:00 PM
RNS
Previous Announcement Regarding Appointment Of NED
25 Sep 2018 01:15 PM
RNS
Overall survival data for Imfinzi: Stage III NSCLC
24 Sep 2018 04:10 PM
RNS
EMA approves AZ's Imfinzi for Stage III NSCLC
24 Sep 2018 07:00 AM
RNS
Farxiga gets positive result in DECLARE-TIMI 58
14 Sep 2018 07:00 AM
RNS
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07 Sep 2018 07:00 AM
RNS
Tezepelumab FDA Breakthrough Therapy Designation
06 Sep 2018 07:00 AM
RNS
Directorate Change
03 Sep 2018 03:00 PM
RNS
Total Voting Rights
31 Aug 2018 07:00 AM
RNS
AstraZeneca Update on Anifrolumab in SLE
30 Aug 2018 07:00 AM
RNS
EC approves Bydureon BCise device for T2 diabetes
23 Aug 2018 07:00 AM
RNS
AstraZeneca PIIIb trial update for Bevespi in COPD
21 Aug 2018 07:00 AM
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings